



Cite this: *Org. Biomol. Chem.*, 2020,  
**18**, 3288

## Targeting STAT3 anti-apoptosis pathways with organic and hybrid organic–inorganic inhibitors†

Matthew B. Minus,<sup>a,b</sup> Haopei Wang,<sup>b</sup> Jaime O. Munoz,<sup>c</sup> Alexandra M. Stevens,<sup>c</sup> Alicia E. Mangubat-Medina,<sup>b</sup> Michael J. Krueger,<sup>c</sup> Wei Liu,<sup>c</sup> Moses M. Kasembeli,<sup>d</sup> Julian C. Cooper,<sup>b</sup> Mikhail I. Kolosov,<sup>e</sup> David J. Twardy,<sup>d,f</sup> Michele S. Redell<sup>c</sup> and Zachary T. Ball  <sup>\*,b</sup>

Recurrence and drug resistance are major challenges in the treatment of acute myeloid leukemia (AML) that spur efforts to identify new clinical targets and active agents. STAT3 has emerged as a potential target in resistant AML, but inhibiting STAT3 function has proven challenging. This paper describes synthetic studies and biological assays for a naphthalene sulfonamide inhibitor class of molecules that inhibit G-CSF-induced STAT3 phosphorylation in cellulo and induce apoptosis in AML cells. We describe two different approaches to inhibitor design: first, variation of substituents on the naphthalene sulfonamide core allows improvements in anti-STAT activity and creates a more thorough understanding of anti-STAT SAR. Second, a novel approach involving hybrid sulfonamide–rhodium(II) conjugates tests our ability to use cooperative organic–inorganic binding for drug development, and to use SAR studies to inform metal conjugate design. Both approaches have produced compounds with improved binding potency. *In vivo* and *in cellulo* experiments further demonstrate that these approaches can also lead to improved activity in living cells, and that compound **3aa** slows disease progression in a xenograft model of AML.

Received 18th December 2019,  
Accepted 19th March 2020

DOI: 10.1039/c9ob02682g  
rsc.li/obc

## Introduction

Signal transducer and activator of transcription (STAT) proteins are intracellular signaling proteins that mediate response to extracellular stimuli.<sup>1–3</sup> Extracellular signaling proteins, such as cytokines and growth factors, activate membrane-bound receptors that then recruit and tyrosine phosphorylate the STAT3 loop domain immediately C-terminal to the SH2 domain.<sup>4</sup> Phosphorylated STAT3 (pSTAT3) dimerizes and translocates to the nucleus where it activates transcription of tumor survival pathways.<sup>5,6</sup> The aberrant activation of STAT3 is a common occurrence in many cancers.<sup>6,7</sup> Inhibition of STAT3 activity has been shown to lead to apoptosis in cancers such as breast,<sup>8,9</sup> head and neck,<sup>10,11</sup> colon,<sup>12</sup> liver,<sup>13</sup> acute myeloid

leukemia (AML),<sup>14,15</sup> and prostate.<sup>16</sup> Thus, STAT3 has been implicated as a promising protein target for the development of broad-spectrum chemotherapeutics.<sup>17</sup>

In spite of significant efforts, inhibiting STAT3 pathways has proven difficult.<sup>18</sup> Blocking intracellular protein–protein interactions like those that mediate STAT3 activation remains a daunting pharmacological goal.<sup>19,20</sup> We became interested in naphthalene sulfonamides as anti-STAT3 compounds,<sup>4,11,14,21</sup> and sought to understand the molecular basis of STAT3 binding, to identify their molecular target on STAT3, and to assess the anti-AML activity of these compounds in molecular, cellular, and animal models of AML. We began this exploration assuming that the lead compound, **C188-9** (a.k.a. TTI-101) (Fig. 1b), competitively binds to the phosphotyrosine peptide binding site in SH2 domain, consistent with previous assumptions (Fig. 1a). During the course of our investigations, rhodium-catalyzed proximity-driven covalent modification determined that modified naphthalene sulfonamides also target a new binding site in the coiled-coil domain (CCD), and that, importantly, binding to this site is not competed by the natural phosphotyrosine peptide (Fig. 1a, orange residue).<sup>15</sup> In part, current research seeks to investigate the therapeutic potential of targeting CCD.<sup>15</sup>

At the same time, the challenges of STAT3 inhibition provided an opportunity to explore an unconventional approach to inhibitor development: employing rhodium–small molecule

<sup>a</sup>Prairieview A&M University, Prairie View, TX, 77446, USA

<sup>b</sup>Department of Chemistry, Rice University, Houston, TX 77005, USA

E-mail: [zb1@rice.edu](mailto:zb1@rice.edu)


<sup>c</sup>Baylor College of Medicine, Texas Children's Cancer Center, Houston, TX 77030, USA

<sup>d</sup>Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

<sup>e</sup>Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA

<sup>f</sup>Department of Molecule and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

† Electronic supplementary information (ESI) available. See DOI: [10.1039/c9ob02682g](https://doi.org/10.1039/c9ob02682g)



**Fig. 1** (a) Crystal structure of a single STAT3 protein when bound as a dimer to duplex DNA.<sup>22</sup> Nucleophilic ligands, cysteine and methionine residues of the SH2 domain (purple) and aspartate ligands of the coiled-coil domain (blue) are highlighted. Affinity labeling experiments with a rhodium inhibitor conjugate indicates that binding occurs at/near Phe174 (orange) in the coiled-coil domain. (b) A lead compound, C188-9 (a.k.a. TTI-101). (c) Rh-STAT3 conjugates use inorganic–organic cooperativity to bind STAT3.

conjugates as anti-STAT agents. Conceptually, the approach is based on cooperative organic–inorganic binding that includes rhodium coordination to a Lewis-basic side chain near protein binding interface (Fig. 1c).<sup>22,23</sup> We have demonstrated this concept with rhodium–peptide conjugates, and this work provided an opportunity to explore the concept with non-peptide inhibitors (Fig. 1c). Cellular studies provided an opportunity to assess function in living cells, as opposed to purely biophysical measurements, and these measurements shed light on the benefits and limitations of rhodium-based approaches, compared to traditional small-molecule STAT3 inhibitors.

## Inhibitor synthesis

Naphthalene sulfonamides were identified as lead fragments through a combination of screening and limited structural variation.<sup>21</sup> Compounds with STAT3-binding activity permit significant variation of the sulfonamide substituent ( $R^3$  in Fig. 2), thus  $R^3$  was seen as the most straightforward site for incorporation of rhodium centers, *via* target structures such as 13aa–13c. Furthermore, the C5–C8 positions of the naphthalene ring ( $R^4$ ) were a largely unexplored site of variation. In the course of our studies, we became further interested in variation of the naphthalene, and in assessing the function of redox variants of this core, such as the iminoquinone (Fig. 2).

In the synthetic direction, the requisite 2-substituted naphthalene sulfonamides (e.g. 2a–4d, Scheme 1) are readily available *via* elaboration of simple naphthalene sulfonamides (1a–1f, Scheme 1) after sulfonamide formation from 4-amino-1-naphthol. Formation of the sulfonamide early in the synthesis is important to limit synthetic manipulations with oxidatively sensitive free 4-amino-1-naphthol derivatives. Elaboration of the 2-position of the naphthalene ring with halogens is directly achieved by electrophilic aromatic substitution to afford arylbromides (2a–2c). Alternatively, oxidative coupling with pro-nucleophiles (Nu–H = Ar–H, RS–H, RO–H) succeeds *via* the intermediacy of an iminobenzoquinone 1a<sup>ox</sup>–1f<sup>ox</sup>.<sup>25</sup> This allowed preparation of a variety of additional S-linked (3aa–3cd) and C-linked (4a–4d) 2-substitution products.

In tandem, we set our sights on 8-substituted derivatives that could provide electronic and steric perturbation of the naphthalene core, both to investigate SAR in this region and to perturb the redox stability of inhibitor molecules. In a first approach, (Scheme 2), we synthesized 1,8-difluoronaphthalene from 1,8-diaminonaphthalene,<sup>26</sup> *via* a bis-diazonium intermediate. The 1,8-difluoronaphthalene was nitrated at the 4-position (5), and nucleophilic aromatic substitution of the fluorine *para* to nitro with an alkoxide delivered naphthyl ether, and subsequent hydrogenolysis yield 7. Efforts in this direction were limited by safety and scalability concerns: the bis-diazonium salt was prone to spontaneous and at times






Fig. 2 Previously established STAT3 inhibitor motif,<sup>21</sup> and expanded motifs discovered in this work.



Scheme 1 Modular synthesis of STAT3 inhibitors (a)  $R^1SO_2Cl$ , pyridine, MeCN,  $MgSO_4$  (32–94%) (b)  $Br_2$ ,  $CH_2Cl_2$  (25–60%) (c)  $Phl(OAc)_2$ , acetone (d)  $PhSH$ ,  $HCOOH$  (26–85%) (e)  $BF_3\cdot Et_2O$ , 2-naphthol (30–70%). Yields for oxidative coupling were taken over 2 steps. (\*) Inhibitor isolated as oxidized iminonaphthoquinone.

violent decomposition. As an alternative, we exploited more recent advances<sup>27</sup> in nucleophilic aromatic fluorination to prepare **6** from 1,5-dinitronaphthalene (Scheme 2). This route gave better access to fluorinated naphthalene intermediates. The electrophilic naphthalene ring **6** could be oxidized with *tert*-butylhydroperoxide (TBHP) in liquid ammonia to install a

hydroxyl group, affording naphthalen **7**. Etherification of the OH group was next performed, providing a benzyl (**8**) or methyl (**10**) ether. At this point, the nitro group could be reduced selectively in the presence of a platinum catalyst, and the resulting aniline then coupled with a sulfonyl chloride to provide sulfonamide **8**. Deprotection of the benzyl group and



**Scheme 2** Synthesis of 5-fluoronaphthylsulfonamides (a) (i)  $\text{HBF}_4$  (aq)  $\text{NaNO}_2$  (ii) molten  $\text{KHF}_2$  (2–20%) (b)  $\text{HNO}_3$ ,  $\text{NaNO}_2$  (60%) (c)  $\text{BnOH}$ ,  $\text{NaH}$ ,  $\text{CH}_2\text{Cl}_2$  (61%) (d)  $\text{Pt/C}$ ,  $\text{NaBH}_4$  (99%) (e)  $\text{CsF}$ ,  $\text{DMSO}$ ,  $100\text{ }^\circ\text{C}$  (23%) (f)  $\text{NH}_3$ ,  $\text{TBHP}$ ,  $\text{NaOH}$ ,  $\text{THF}$  (70%) (g)  $\text{BnBr}$ ,  $\text{Cs}_2\text{CO}_3$ ,  $\text{CH}_2\text{Cl}_2$  (75%) (h) (i)  $\text{Pt/C}$ ,  $\text{NaBH}_4$  (ii) 4-methoxybenzenesulfonyl chloride, pyridine,  $\text{MgSO}_4$  (62%) (i)  $\text{Pd/C}$ ,  $\text{H}_2$ , (j)  $\text{Phl(OAc)}_2$ ,  $\text{PhSH}$ ,  $(\text{CF}_3)_2\text{CHOH}$  (37%) (k)  $\text{MeI}$ ,  $\text{K}_2\text{CO}_3$ ,  $\text{DMF}$  (84%) (l) (i)  $\text{Pd/C}$ ,  $\text{NaBH}_4$  (ii)  $\text{R}_2\text{SO}_2\text{Cl}$ , pyridine,  $\text{MgSO}_4$  (45–89%) (m)  $\text{Br}_2$ ,  $\text{CH}_2\text{Cl}_2$  (56–75%).

oxidative coupling with thiophenol gave fluoride 9. Alternatively, the methyl ethers 12a and 12b were synthesized as analogues of compounds 2a–2c.

Several structures with different ester functional groups serve as anchor points for rhodium conjugation (4a, 4b, 4c in Table 1). General methods that have been previously reported allow for facile cooperative rhodium(II) binding to neighboring residues that strongly coordinate to metal centers, such as methionine or histidine, allowed 50–500 fold increases in potency in other systems.<sup>23,24,28</sup> The presumptive target of naphthalene sulfonamide inhibitors, the SH2 domain, contained several such residues (Fig. 1a, purple). However, the coiled coil domain—later identified as another target of naphthalene sulfonamide inhibitors—is devoid of histidine, cysteine, and methionine residues. This discovery allowed us to assess the suitability of cooperative inhibition with rhodium conjugates toward binding sites that lack such strong metal-binding sites (Fig. 1a, blue). We chose to append esters onto the C4 substituent of the naphthalene ring (Fig. 2), a region of the inhibitor which was previously found to be tolerant to steric and electronic variations.<sup>21</sup> We prepared several rhodium conjugates from ester-containing intermediates by acidic hydrolysis followed by metalation with a heteroleptic rhodium reagent containing labile trifluoroacetate groups (Table 1). Unfortunately, Rh-naphthylsulfonamide conjugates could not be made by traditional procedures that involve refluxing the carboxylate inhibitors in benzene. These conditions proved to be too harsh for the organic starting materials. Instead methodologies previously developed by our

group were used to successfully couple these small molecules to rhodium.<sup>15</sup>

## SPR analysis

Potency was initially assessed by surface plasmon resonance (SPR), allowing quantification of binding and straightforward comparison to other studies.<sup>21</sup> Variation of the  $\text{R}^1$  and  $\text{R}^2$  groups provided additional insight into the structural landscape of affinity. A perfluorinated ring within compound 2a—suggested by the appearance of this group in another STAT-binding compound,<sup>8,29</sup> results in a 3-fold increase in potency from C188–46 (Table 2). When this change was combined with variation at the C2 position, significant gains in affinity were observed. Compound 3aa was found to be 10-fold more potent than 2a. Being inspired by this increase in potency, we made different analogues of the inhibitors. In general inhibitors with thiophenyl in the C2 position displayed greater potency. Even when the perfluorinate ring in the  $\text{R}^1$  position was replaced with another alkyl or aryl group, the potency remained similar. In addition, it seems the thiophenyl ring is functionally tolerant to hydroxylation and alkylation. Inhibitors (3cb–3cd) were only slightly less potent than their parent compound (3ca). In summary, SPR analysis demonstrates that molecular recognition of the inhibitor to STAT3 is dependent on the 1,2,4 substitution on the naphthalene ring. This is highlighted by the fact that smaller molecules without the sulfonamide-like moiety (14–16) still inhibit STAT3-phosphopeptide binding.

Table 1 Preparation of rhodium conjugates by carboxylate exchange with heteroleptic rhodium trifluoroacetates

Entry	$\text{linker}-\text{CO}_2\text{Me}$	Product	$\text{R}^1$	$\text{R}^2$	$\text{R}^3$	Yield (%)
1		13aa	Me	Me	Me	63
2		13ab	<sup>n</sup> Bu	<sup>n</sup> Bu	<sup>n</sup> Bu	15
3		13ac	Fluorescein	Me	Me	21
4		13ad	n.a.	Me	Me	15
5		13ae	CF <sub>3</sub>	Me	Me	42
6		13af	CF <sub>3</sub>	CF <sub>3</sub>	CF <sub>3</sub>	15
7		13b	Me	Me	Me	37
8		13c	Me	Me	Me	8

## Naphthalene sulfonamide oxidation

The 1,4-substitution pattern of hydroxyl-naphthalenesulfonamides renders the core structure susceptible to oxidation. Some synthetic intermediates (*i.e.* **1b**, **1c**, and **1f**) indeed proved quite prone to air oxidation and subsequent decomposition. *In vivo* oxidation could be a decomposition pathway, but it is also possible that oxidized iminoquinone species (*e.g.* Table 2, **2b\***) may represent an active species, with naphthalenesulfonamides serving as a pro-drug. Iminoquinone structures might serve as reactive electrophiles for covalent inhibition pathways, and in this sense they might putatively share features in common with other known STAT3 inhibitors, such as LY5<sup>30</sup> and BA-TPQ<sup>31</sup> with structures consistent with electrophilic reactivity. Significant decomposition of **C188-9** was observed within 4 hours in aqueous buffer under air (Fig. S1†), and crude NMR investigations showed new peaks consistent with an iminoquinone. In one case, an iminoquinone intermediate **2b\*** (Table 2) was stable enough to be isolated, characterized, and tested. This iminoquinone also demonstrated significant binding affinity in our SPR-based assay, suggesting

that iminoquinone intermediates may contribute to at least some function *in vivo*.

To further probe these issues, we prepared a brief series of **C188-9** analogues with an explicit goal of improving lifetime in media. Although some structural changes abrogated binding, a few did show promising binding by SPR, including fluoro-ether **12b** and triflate **19** (Table 2). Interestingly, *O*-acylation of the naphthol hydroxyl group has a significant negative effect on binding in the case of **17**, but substitution on oxygen is tolerated in other cases (*e.g.* **12b**, **18**, and **19**). Unlike the parent **C-188-9**, fluoro-ether **12b** and triflate **19** are indefinitely stable in aqueous buffer in air. The binding potency of **12b** and **19** suggests that oxidation and/or accessing an iminoquinone structure is not required for binding or activity.

## Inhibition of intracellular phosphorylation

The more promising molecules (**3aa-3ca**) were tested in intracellular STAT3 phosphorylation assays. To extrapolate intra-

**Table 2** Inhibition of STAT3 phosphopeptide binding. Inhibitive potency ( $IC_{50}$ ) was determined by established SPR and/or a cellular STAT3 phosphorylation assay

	SPR $IC_{50}$ ( $\mu$ M)		SPR $IC_{50}$ ( $\mu$ M)	pSTAT3 $IC_{50}$ ( $\mu$ M)		SPR $IC_{50}$ ( $\mu$ M)	pSTAT3 $IC_{50}$ ( $\mu$ M)
14	72		0.1			8	8.6
15	68	3aa, MM-206	0.7	8.7		50	20
16	20						11.7
			0.8	12		2	5.7
c188-9	4						
c188-19	2						
			0.9	7.3		>100	
c188-46	24						
			2			4	
c188-47	49						
			4	4.6		5	26
2a	8						
			1	16			
2b*	0.2						
			25	33			


cellular potency, Kasumi-1 human AML cells were treated with differing concentrations of inhibitor (Fig. 3a). Cells were incubated with granulocyte-colony stimulating factor (G-CSF) to induce STAT3 phosphorylation.<sup>32</sup> After incubation, the cells were lysed and levels of STAT3 phosphorylated on tyrosine 705 (pSTAT3) were quantified with a fluorescent pSTAT3 antibody. Although **3aa**, **3ba**, and **3ca** performed similarly by SPR (Table 2), their ability to inhibit STAT3 phosphorylation in cells was markedly different. This suggests that their molecular recognition of STAT3 in an isolated system like SPR is similar, however, in a protein-rich redox-buffered environment these

inhibitors no longer behave the same. It is important to note that differences in small molecule specificity and cellular uptake can also affect the intracellular potency of the inhibitors. Nevertheless, **3aa** was clearly the most potent small-molecule pSTAT3 inhibitor.

We wanted to ensure that the molecule **3aa** also inhibits inducible STAT3 phosphorylation in other AML cell lines (Fig. 3b). Following a 30-minute treatment with **3aa** prior to G-CSF stimulation, all three of the AML cell lines tested (HL-60, MOLM-13, and Kasumi-1) exhibited dose-dependent decreases in STAT3 phosphorylation with  $IC_{50}$  0.8–1.9  $\mu$ M. This demonstrates that the anti-pSTAT3 activity of **3aa** can be seen across different AML cell lines.

To further evaluate the therapeutic potential of **3aa**, we confirmed its ability to induce apoptosis in different AML cell lines and primary tumor cells from pediatric AML patients. Cells were incubated with different doses of each inhibitor and subsequently incubated with fluorescent Annexin V. Annexin V binds to apoptotic cells, and FITC-Annexin V conjugates allow quantification of apoptosis by fluorescence assisted cell sorting (FACS). A 24-hour treatment with **3aa** increased apoptosis in all AML cell lines and primary samples tested (Fig. 3c). In contrast, acute lymphoblastic leukemia (ALL) cell lines—which do not have upregulated STAT3 activity<sup>33</sup>—were much less sensitive to apoptosis induction (Fig. 3c, KOPN-8 and RS4-11). These findings are consistent with the idea that **3aa** inhibits STAT3 phosphorylation in AML cell lines and induces apoptosis through that mechanism of action.

After thoroughly investigating our **3aa** in the *in vitro* models, we moved to investigate its potency in *in vivo* mouse models. STAT3-dependent cytotoxicity in apoptosis assays suggested at least a half-log dosing window. Mice were injected intravenously with MV4-11 human AML cells. After two weeks, mice were treated for another 2–4 weeks with **3aa**. Results from *in vivo* imaging, bone marrow and spleen harvesting indicate that **3aa** increases mouse survival by decreasing the expansion of MV4-11 leukemia cells (Fig. 3d–f).



**Fig. 3** Portions of this figure were adapted from a preliminary report.<sup>15</sup> Compound **3aa** inhibits G-CSF-induced STAT3 phosphorylation, induces apoptosis in human AML cells, and slows disease progression in a xenograft model of AML. \*\*\* (a) Histogram of decrease in pSTAT3 in Kasumi-1 cells. (b) **3aa** inhibits G-CSF-induced pSTAT3 in multiple AML cell lines. Legend values indicate  $IC_{50}$  values. Mean  $\pm$  SD for  $n = 3$ . (c) Apoptosis quantified in Annexin V-FITC-labeled cells treated with 10 for 24 h. Spontaneous apoptosis in untreated cells was subtracted to yield the % apoptosis attributable to drug. Data shown for an AML cell line (MV4-11, HL-60) and primary patient-derived AML cells (p198) compared to ALL cell lines (KOPN-8, RS4-11) as a negative control. (d and e) NSG mice were injected iv with  $10^6$  MV4-11. ffluc AML cells at day 0. After two weeks, mice received compound 10, 30 mg kg<sup>-1</sup> ( $n = 8$ ), or vehicle ( $n = 6$ ), ip daily 5 d per week for 4 weeks (weeks 2–6). (d) Luminescence images one week after treatment. Colorized signal intensity indicates amount of active disease, from low (blue) to high (red). (e) The percent of MV4-11 cells in bone marrow and spleen was evaluated by flow cytometry at the time of euthanasia. \* $P < 0.05$  (f) disease burden was measured non-invasively by bioluminescence weekly. Each line represents the trajectory of an individual mouse. Mice were euthanized when moribund or at the end of 8 weeks.

### Rhodium conjugates as STAT3 inhibitors

After garnishing some promising results in the traditional small molecule studies with **3aa**, we shifted our focus to the biological efficacy of small molecule-rhodium conjugates. Again, we used SPR to screen inhibitor potency (Table 3). Rhodium-inhibitor conjugate **13aa**, **13ac**, and **13b**, showed potency increases over their analogous esters. Compared to previous studies with other binding sites, this affinity gain is rather modest, and is presumably consistent with at most very weak binding to side chains such as carboxylates (*i.e.* residue Asp 170 near the coiled-coil binding site) rather than stronger binding to histidine or methionine. A previous study found that sterically demanding carboxylates improved the decomposition half-life of rhodium complexes,<sup>34</sup> but the sterically crowded rhodium complex **13ac** had potency similar to other rhodium conjugates. The divalent structure **13ad** did demonstrate moderately improved STAT3 affinity (0.1  $\mu$ M).

**Table 3** SPR analysis of binding for carboxylate-containing and rhodium-conjugate compounds

Entry	cmpd	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	SPR IC <sub>50</sub> (μM)	
					ester	Rh(II)
1	<b>13aa</b>	Me	Me	Me	25	1
2	<b>13ab</b>	<sup>n</sup> Bu	<sup>n</sup> Bu	<sup>n</sup> Bu	25	0.6
3	<b>13ac</b>	Fluorescein	Me	Me	25	1
4	<b>13ad</b>	n.a.	Me	Me	25	0.1
5	<b>13ae</b>	CF <sub>3</sub>	Me	Me	25	0.04
6	<b>13af</b>	CF <sub>3</sub>	CF <sub>3</sub>	CF <sub>3</sub>	25	0.2
7	<b>13b</b>	Me	Me	Me	8	1
8	<b>13c</b>	Me	Me	Me	50 <sup>a</sup>	0.3

<sup>a</sup> SPR IC<sub>50</sub> of the carboxylic acid derivative **4c** was measured.


It seemed possible that a more Lewis-acidic rhodium center could benefit from more potent binding to peripheral residues.<sup>35</sup> The coiled-coil domain does have several carboxylate side chains near the ligand-binding site (Fig. 1a, blue), including Asp170, and we reasoned that carboxylates, while weaker ligands than histidine or methionine, might be sufficient ligands for a metal center with increased Lewis acidity. Alteration of the ancillary ligands on rhodium allows tuning the Lewis acidity of the metal center. An electron-poor variant, **13ae** did show improved binding to STAT3 (IC<sub>50</sub> = 0.04 μM, Table 3): compound **13ae** is 100× more potent than **C188-9**, and 25× more potent than the nearly isosteric rhodium complex **13aa**. This effect may be quite subtle: the analogous tris-trifluoroacetate complex (**13af**) exhibited a more modest affinity enhancement (IC<sub>50</sub> = 0.2 μM, Table 3), perhaps reflecting a subtle balance of competitive water binding.<sup>34</sup>

Next, we examined the cellular activity of the lead rhodium conjugate on STAT3 phosphorylation and the induction of apoptosis in Kasumi cells (Fig. 4). To provide a useful comparison, rhodium conjugates were directly compared against **C188-9** and compound **4a**, an isoelectric organic analogue without the capacity for cooperative organic–inorganic binding. In STAT3 intracellular phosphorylation assays (Fig. 4b), the electronically-perturbed rhodium complex **13ae** again exhibited significantly improved activity. The Kasumi cells were exceptionally resistant to both **C188-9** and **4a**, while

**13ae** inhibited STAT3 phosphorylation at lower micromolar potencies. In all, this is the first example of rhodium complexation enhancing the potency of any intracellular inhibitor in cellular assays and these results indicate that rhodium conjugation is a viable strategy for increasing the potency of a biological probe for intracellular assays.

In order to see if this increase phosphorylation inhibition translated to induction of apoptosis, we compared **13ae**, **4a**, and **C188-9** in an Annexin assay (Fig. 4c). The rhodium complex **13ae** was more potent than both **C188-9** and **4a**, which is in agreement with the phosphorylation inhibition results. Therefore the fact that **13ae** consistently outperformed **C188-9** in these *in vitro* assays suggests further development of rhodium conjugates is warranted.

Naphthalene sulfonamides are a useful class of probes to alter STAT3 function. Optimization of the sulfonamide core allowed development of **3aa**, an inhibitor with improved binding potency, and anti-STAT3 activity in cells. Some of the naphthalene sulfonamides also display *in vivo* activity in relevant cancer models.<sup>11,36</sup> For example, pentafluoro compound **3aa**, significantly decreases tumor progression in a mouse model of AML. Anti-phosphorylation activity correlates well with apoptosis induction in tumor models for the naphthalene sulfonamide compound class, again consistent with a specific STAT3-driven mode of action. Overall, optimization of the naphthalene sulfonamide core has resulted in modest gains in potency and activity, perhaps due to innate features of the coiled-coil binding site, which lacks a deep ligand-binding pocket. This limited optimization success led us to pursue tandem efforts to explore rhodium conjugates as potential solution to vexing inhibitor-development problems. The substantial increase in potency observed with rhodium complex **13ae** indicates that significant gains in binding affinity are possible, even without proximal strong metal-binding residues (histidine, methionine, cysteine), by perturbing the electronic structure of the rhodium center in favor of increased Lewis acidity. Perhaps most importantly, the improvement in STAT3 binding carries through to cell-based assays, supporting our previous conclusions that rhodium complexes can enter and act within living cells. Complexes such as **13ae** may serve as probe compounds with unique specificity; although many



**Fig. 4** (a) Small molecules inhibit STAT3/phosphopeptide (p1068) binding. STAT3 phosphopeptide binding was measured with established SPR protocols.<sup>21</sup> (b) Kasumi cells were treated with G-CSF and then with inhibitors. Cells were analyzed for phosphorylated STAT3 (pSTAT3). (c) Apoptosis was measured 24 h after treatment of AML cells with STAT3 inhibitors.

important questions remain, especially regarding *in vivo* application of these compounds.

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

M. B. M. was supported by a Ruth L. Kirchstein National Service Award (NIH F31CA180696). We acknowledge support from the NIH (5R21CA170625), from the Robert A. Welch Foundation Research Grant C-1680 (Z. T. B.), the National Science Foundation (CHE-1904865, Z. T. B.), the Gillson Longenbaugh Foundation (M. S. R.), the Virginia and L. E. Simmons Family Foundation, and the MD Anderson Foundation (D. J. T.).

## References

- 1 J. Bromberg, *J. Clin. Invest.*, 2002, **109**, 1139–1142.
- 2 J. E. Darnell, I. M. Kerr and G. R. Stark, *Science*, 1994, **264**, 1415–1421.
- 3 T. Kisseeva, S. Bhattacharya, J. Braunstein and C. W. Schindler, *Gene*, 2002, **285**, 1–24.
- 4 A. Chakraborty, K. F. Dyer, M. Cascio, T. A. Mietzner and D. J. Twardy, *Blood*, 1999, **93**, 15–24.
- 5 P. Wu, D. Wu, L. Zhao, L. Huang, G. Shen, J. Huang and Y. Chai, *Oncotarget*, 2016, **7**, 19863–19883.
- 6 M. Z. Kamran, P. Patil and R. P. Gude, *BioMed Res. Int.*, 2013, **2013**, 421821.
- 7 D. E. Johnson, R. A. O'Keefe and J. R. Grandis, *Nat. Rev. Clin. Oncol.*, 2018, **15**, 234–248.
- 8 X. Zhang, P. Yue, B. D. G. Page, T. Li, W. Zhao, A. T. Namanja, D. Paladino, J. Zhao, Y. Chen, P. T. Gunning and J. Turkson, *Proc. Natl. Acad. Sci. U. S. A.*, 2012, **109**, 9623–9628.
- 9 Y. Chen, M. Ji, S. Zhang, N. Xue, H. Xu, S. Lin and X. Chen, *J. Drug Targeting*, 2018, **26**, 920–930.
- 10 J. L. Geiger, J. R. Grandis and J. E. Bauman, *Oral Oncol.*, 2016, **56**, 84–92.
- 11 U. Bharadwaj, T. K. Eckols, X. Xu, M. M. Kasembeli, Y. Chen, M. Adachi, Y. Song, Q. Mo, S. Y. Lai and D. J. Twardy, *Oncotarget*, 2016, **7**, 26307–26330.
- 12 J. H. Park, H. van Wyk, D. C. McMillan, J. Quinn, J. Clark, C. S. D. Roxburgh, P. G. Horgan and J. Edwards, *Clin. Cancer Res.*, 2017, **23**, 1698–1709.
- 13 G. He and M. Karin, *Cell Res.*, 2011, **21**, 159–168.
- 14 M. S. Redell, M. J. Ruiz, T. A. Alonzo, R. B. Gerbing and D. J. Twardy, *Blood*, 2011, **117**, 5701–5709.
- 15 M. B. Minus, W. Liu, F. Vohidov, M. M. Kasembeli, X. Long, M. Krueger, A. Stevens, M. I. Kolosov, D. J. Twardy, M. S. Redell and Z. T. Ball, *Angew. Chem., Int. Ed.*, 2015, **54**, 13085–13089.
- 16 J. Abdulghani, L. Gu, A. Dagvadorj, J. Lutz, B. Leiby, G. Bonuccelli, M. P. Lisanti, T. Zellweger, K. Alanen, T. Mirtti, T. Visakorpi, L. Bubendorf and M. T. Nevalainen, *Am. J. Pathol.*, 2008, **172**, 1717–1728.
- 17 H. Yu, H. Lee, A. Herrmann, R. Buettner and R. Jove, *Nat. Rev. Cancer*, 2014, **14**, 736–746.
- 18 P. A. Johnston and J. R. Grandis, *Mol. Interventions*, 2011, **11**, 18–26.
- 19 C. V. Dang, E. P. Reddy, K. M. Shokat and L. Soucek, *Nat. Rev. Cancer*, 2017, **17**, 502–508.
- 20 G. L. Verdine and L. D. Walensky, *Clin. Cancer Res.*, 2007, **13**, 7264–7270.
- 21 X. Xu, M. M. Kasembeli, X. Jiang, B. J. Twardy and D. J. Twardy, *PLoS One*, 2009, **4**, e4783.
- 22 Z. Ren, X. Mao, C. Mertens, R. Krishnaraj, J. Qin, P. K. Mandal, M. J. Romanowski, J. S. McMurray and X. Chen, *Biochem. Biophys. Res. Commun.*, 2008, **374**, 1–5.
- 23 R. Kundu, P. R. Cushing, B. V. Popp, Y. Zhao, D. R. Madden and Z. T. Ball, *Angew. Chem., Int. Ed.*, 2012, **51**, 7217–7220.
- 24 F. Vohidov, S. E. Knudsen, P. G. Leonard, J. Ohata, M. J. Whealon, B. V. Popp, J. E. Ladbury and Z. T. Ball, *Chem. Sci.*, 2015, **6**, 4778–4783.
- 25 H. Ma, S. Wu, Q. Sun, H. Li, Y. Chen, W. Zhao, B. Ma, Q. Guo, Z. Lei and J. Yan, *Synthesis*, 2010, 3295–3300.
- 26 F. B. Mallory, C. W. Mallory and M. C. Fedarko, *J. Am. Chem. Soc.*, 1974, **96**, 3536–3542.
- 27 S. D. Schimler, S. J. Ryan, D. C. Bland, J. E. Anderson and M. S. Sanford, *J. Org. Chem.*, 2015, **80**, 12137–12145.
- 28 B. V. Popp and Z. T. Ball, *J. Am. Chem. Soc.*, 2010, **132**, 6660–6662.
- 29 B. D. G. Page, S. Fletcher, P. Yue, Z. Li, X. Zhang, S. Sharmin, A. Datti, J. L. Wrana, S. Trudel, A. D. Schimmer, J. Turkson and P. T. Gunning, *Bioorg. Med. Chem. Lett.*, 2011, **21**, 5605–5609.
- 30 C. Zhao, W. Wang, W. Yu, D. Jou, Y. Wang, H. Ma, H. Xiao, H. Qin, C. Zhang, J. Lü, S. Li, C. Li, J. Lin and L. Lin, *Oncotarget*, 2016, **7**, 12917–12926.
- 31 W. Wang, E. R. Rayburn, S. E. Velu, D. Chen, D. H. Nadkarni, S. Murugesan, D. Chen and R. Zhang, *Breast Cancer Res. Treat.*, 2010, **123**, 321–331.
- 32 K. Shimozaki, K. Nakajima, T. Hirano and S. Nagata, *J. Biol. Chem.*, 1997, **272**, 25184–25189.
- 33 Y. Furuichi, K. Goi, T. Inukai, H. Sato, A. Nemoto, K. Takahashi, K. Akahane, K. Hirose, H. Honna, I. Kuroda, X. Zhang, K. Kagami, Y. Hayashi, K. Harigaya, S. Nakazawa and K. Sugita, *Cancer Res.*, 2007, **67**, 9852–9861.
- 34 M. B. Minus, M. K. Kang, S. E. Knudsen, W. Liu, M. J. Krueger, M. L. Smith, M. S. Redell and Z. T. Ball, *Chem. Commun.*, 2016, **52**, 11685–11688.
- 35 J. M. Coughlin, R. Kundu, J. C. Cooper and Z. T. Ball, *Bioorg. Med. Chem. Lett.*, 2014, **24**, 5203–5206.
- 36 K. H. Jung, W. Yoo, H. L. Stevenson, D. Deshpande, H. Shen, M. Gagea, S.-Y. Yoo, J. Wang, T. K. Eckols, U. Bharadwaj, D. J. Twardy and L. Beretta, *Clin. Cancer Res.*, 2017, **23**(18), 5537–5546.